More tools:Markets·Screener·Research·Chat

Novavax Inc (NVAX) Financial Statements

Novavax Inc
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SGL8G3
XNAS · usd
9.93▼ 0.26 (-2.55%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close10.19
Day's Range9.75 – 10.36
52-Week Range6.20 – 11.97
Volume4.2M
Avg Volume4.5M
Share Statistics
Shares Outstanding
Employees749
ExchangeXNAS
Listed1995-12-05
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Novavax Inc (NVAX)
What is Novavax Inc's Market Cap?
Novavax Inc's Market Cap is $1.6B, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's Enterprise Value?
Novavax Inc's Enterprise Value is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's Price / Sales?
Novavax Inc's Price / Sales is 4.0×, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's EV / Revenue?
Novavax Inc's EV / Revenue is 2.9×, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's EV / EBITDA?
Novavax Inc's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's Revenue (TTM)?
Novavax Inc's Revenue (TTM) is $413.8M, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's Net Income (TTM)?
Novavax Inc's Net Income (TTM) is -$247.7M, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's EBITDA?
Novavax Inc's EBITDA is -$216.3M, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's Diluted EPS (TTM)?
Novavax Inc's Diluted EPS (TTM) is -1.50, based on as-reported figures from SEC (XBRL) filings.
What is Novavax Inc's EBITDA Margin?
Novavax Inc's EBITDA Margin is -52.3%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth-76.3%-79.1%+66.6%-16.6%
Expenses:
Cost of sales
Research and development
Selling, general, and administrative
Total expenses
% of revenue196.8%111.1%90.3%352.7%
Income (loss) from operations
% of revenue-96.8%-11.1%9.7%-252.7%
Other income (expense):
Interest expense
Other income, net
Income (loss) before income tax expense
Income tax expense
Net income (loss)
% of revenue-94.2%-6.8%11.9%-287.3%
Basic (in usd per share)
Diluted (in usd per share)